Pharma Cos. Get Bystolic Generic Delay Claims Tossed

By J. Edward Moreno (January 24, 2022, 5:55 PM EST) -- A New York federal judge dismissed claims brought against AbbVie and other pharmaceutical firms by direct purchasers including Walgreens and CVS as well as claims brought by end payers who accused the drugmakers of conspiring to keep generic forms of the blockbuster hypertension drug Bystolic off the market.

In the one-page order filed Monday, U.S. District Judge Lewis J. Liman granted the pharmaceutical companies' motion to dismiss without prejudice, giving the direct purchasers and end payers, including the city of Baltimore and several union benefits and welfare funds, until Feb. 22 to file an amended complaint. The full order and opinion...

Stay ahead of the curve

In the legal profession, information is the key to success. You have to know what’s happening with clients, competitors, practice areas, and industries. Law360 provides the intelligence you need to remain an expert and beat the competition.


  • Access to case data within articles (numbers, filings, courts, nature of suit, and more.)
  • Access to attached documents such as briefs, petitions, complaints, decisions, motions, etc.
  • Create custom alerts for specific article and case topics and so much more!

TRY LAW360 FREE FOR SEVEN DAYS

Hello! I'm Law360's automated support bot.

How can I help you today?

For example, you can type:
  • I forgot my password
  • I took a free trial but didn't get a verification email
  • How do I sign up for a newsletter?
Ask a question!